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Abstract
Background: The aim of this work was to establish recommendations for the medical follow-up of workers
currently or previously exposed to lung carcinogens.
Methods: A critical synthesis of the literature was conducted. Occupational lung carcinogenic substances were
listed and classified according to their level of lung cancer risk. A targeted screening protocol was defined.
Results: A clinical trial, National Lung Screnning Trial (NLST), showed the efficacy of chest CAT scan (CT) screening
for populations of smokers aged 55–74 years with over 30 pack-years of exposure who had stopped smoking for
less than 15 years. To propose screening in accordance with NLST criteria, and to account for occupational risk
factors, screening among smokers and former smokers needs to consider the types of occupational exposure for
which the risk level is at least equivalent to the risk of the subjects included in the NLST. The working group
proposes an algorithm that estimates the relative risk of each occupational lung carcinogen, taking into account
exposure to tobacco, based on available data from the literature.
Conclusion: Given the lack of data on bronchopulmonary cancer (BPC) screening in occupationally exposed
workers, the working group proposed implementing a screening experiment for bronchopulmonary cancer in
subjects occupationally exposed or having been occupationally exposed to lung carcinogens who are confirmed as
having high risk factors for BPC. A specific algorithm is proposed to determine the level of risk of BPC, taking into
account the different occupational lung carcinogens and tobacco smoking at the individual level.
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Background
In 2012, bronchopulmonary cancer (BPC) was the most
frequently observed cancer, with 1.8 million new cases
across the globe. It is also the leading cause of death by
cancer, with approximately one death out of five, of all
cancers combined [1].
In addition to tobacco consumption, occupational ex-
posure to carcinogenic products is another major risk
factor of BPC, and review studies estimate that the pro-
portion of BPCs attributable to occupational exposure
varies from 13 to 29% in men, the most frequently in-
volved carcinogenic agent being asbestos [2, 3]. Several
professional etiologies have been identified for BPC and
have been the subject of reviews of the literature [4–6].
The confirmed (IARC group 1) carcinogenic agents (and
exposure situations) for which there is over-incidence of
BPC include the following1: asbestos, arsenic (and
arsenic-based compounds), benzo(a)pyrene, beryllium
(and beryllium-based compounds), bis(chloromethyl)
ether and chloromethyl methyl ether, cadmium (and
cadmium-based compounds), hexavalent chromium de-
rivatives, diesel engine emissions, sulfur mustard, coal
tar, coal tar pitch, soot, coal gasification and coke pro-
duction, work in iron and steel foundries, certain nickel
derivatives, plutonium-239, radon-222, X-rays and
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gamma rays and daughter products (work in iron ore
mines), crystalline silica, the painting profession, passive
smoking, talc containing asbestiform fibers, aluminum
production using the Söderberg process, and the rubber
industry.
In 70% of cases, BPC presents with immediate metas-
tases, preferentially located in the liver, bone, brain,
suprarenal glands and the skin. This frequent metastatic
dissemination has an impact on the therapeutic strategy
and prognosis. The median survival in patients present-
ing with clinical stage IA cancer is 58 months and is re-
duced to 6 months for a patient with stage IV cancer [7].
In France, work regulations provide for the implemen-
tation of multidisciplinary occupational health teams
working towards the prevention of occupational risks
(study of exposure, provision of advice, promotion of oc-
cupational health, etc.) and, in cases in which occupa-
tional risk is not totally controlled, reinforced medical
surveillance for subjects who are occupationally exposed
to carcinogenic agents; however, precise details on the
modalities of this surveillance are rarely provided. After
retirement, the implementation of post-occupational
surveillance is also scheduled. It is worth noting that, for
many lung carcinogens and for the exposure to such
agents, post-occupational surveillance (implemented in
1995 in France) continues to provide for lung X-rays
once every 2 years but makes no reference to other im-
aging techniques (chest CAT (CT) scans in particular).
It would therefore appear necessary to reassess the per-
tinence and frequency of the associated medical exami-
nations involved in the surveillance of subjects exposed
to these lung carcinogens. For past asbestos exposure,
previous recommendations in 1999 and 2010 have been
proposed in France to monitor only benign pleuropul-
monary diseases [8, 9]. During post-occupational
surveillance, chest CT scans are recommended for
asbestos-exposed subjects at a frequency of every 5 to 10
years, depending on the cumulative asbestos exposure
after a latency period. In Italy, Mastrangelo et al. pro-
posed in 2013 methods to follow-up workers with past
occupational exposure to asbestos [10]. According to re-
sults published by the National Lung Screening trial
(NLST) (United States) [11], the efficacy of screening by
chest CT scan is based on an annual renewal of the
examination for populations of smokers with a con-
sumption of over 30 pack-years who have stopped smok-
ing for less than 15 years. Following the publication of
the NLST results, recommendations and expert opinions
have been published internationally [12–21]. The major-
ity recommends BPC screening by low-dose chest CT
scan but in strictly controlled conditions. The pertinence
of this type of screening, although assessed in a popula-
tion of smokers, has not yet been evaluated in popula-
tions exposed to other lung carcinogens, in particular
occupational carcinogens. The occupational origin of
BPC is often difficult to determine within a context of
frequently associated tobacco consumption due to the
absence of any clinical, histological or evolutive specifi-
city. Although imputability is difficult to establish at the
individual level, the identification of occupational expos-
ure to carcinogenic agents is nevertheless important, es-
pecially due to the medico-social consequences for the
patients, as they can potentially obtain compensation for
their condition as an occupational disease. This identifi-
cation is equally essential for collective prevention in
order to reinforce prevention in the workplace in the
case of persistent exposure.
The aim of this work is to draft recommendations for
the medico-professional surveillance of workers exposed
or having been exposed to lung carcinogens using the
“Clinical Practice Guidelines” method [22].
Methods
Subjects included in these recommendations are all
workers exposed or having been exposed to lung carcin-
ogens, whether they are active or inactive and regardless
of the type of current or former work contract or profes-
sional status. The occupational carcinogens studied were
occupational carcinogens classified by the WHO (World
Health Organization) IARC as carcinogenic to humans
(group 1) with sufficient evidence in humans regarding
lung cancer.
The subject of our study is vast and raises a number of
questions and sub-questions. The available scientific data
are highly dispersed and difficult to summarize. In this
situation, the most appropriate method, recommended
by the HAS (French National Authority for Health), ap-
pears to be the “Clinical Practice Guidelines” method
[22]. An analysis and critical synthesis of the scientific
literature were conducted according to the principles of
critical reading to attribute a level of scientific proof to
each article based on the classifications proposed by the
HAS [23] (Table 1).
No randomized comparative studies have been con-
ducted on occupational risk factors in the workplace.
However, there have been several “well-conducted” stud-
ies, taking into account confounding factors and poten-
tial dose–response relationships, that report concordant
results. We first selected meta-analyses or systematic re-
views of well-conducted cohorts offering level 2 scien-
tific proof, then cohort studies offering level 2 scientific
proof and, finally, case–control studies offering level 3
scientific proof. The associated recommendation grades
are illustrated in Table 1.
Due to a lack of available studies, certain recom-
mendations are based on expert consensus within the
framework of a working group after consultation
with a reading group. Composition of working group
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(24 members) and reading group (72 members) is
presented in Additional file 1 along with the con-
sulted databases and keywords used.
The scientific rationale used to elaborate the recom-
mendations, established by the project coordinator was
forwarded to all members of the working group. The
working group then amended and/or completed the list
of recommendations to draft a new version. This new
version was sent to the reading group. The comments
offered by the reading group were analyzed by the work-
ing group, which then modified the rationale based on
certain remarks before drafting a final version of the rec-
ommendations. The final version of the rationale and
recommendations, together with the process imple-
mented for their production, was then analyzed by the
HAS Committee for health care strategies and the HAS
College. Because no humans were involved in this study,
no Ethics Committee or Institutional Review Board ap-
proval was necessary. For the same reason, no written
informed consent was necessary.
Results
The flow chart of the search strategy is presented in
Fig. 1. The results of our analysis of the scientific litera-
ture on carcinogenic to humans (group 1) with sufficient
evidence in humans regarding lung cancer were summa-
rized in Additional file 2 with regard to the possible ex-
istence of the following:
– a dose–response relationship in BPC,
Table 1 Recommendation grading
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Fig. 1 Flow diagram
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– a threshold of carcinogenic effects (i.e., a threshold
above which a carcinogenic effect can be detected)
for mean exposure intensity, peak exposure values,
exposure duration or cumulative exposure.
– modeling of the incidence of BPC based on co-
exposures.
Only one large-scale randomized study (n = 53,456),
the NLST, which was conducted in the United States
with subjects aged from 55 to 74 years who were either
active or former smokers (having stopped within the
past 15 years) with a consumption of 30 pack-years or
more, demonstrated the efficacy of low-dose chest CT
scan screening; this study reported a significant 20% re-
duction in mortality by BPC and a 6.7% reduction in
overall mortality compared to screening by chest X-ray
alone [11]. Other randomized clinical trials reported re-
sults on mortality by BPC: three with non-significant re-
sults (DANTE study, DLCST study and MILD study)
[24–26]. Two other randomized clinical trials were on-
going (NELSON, UKLS) [27, 28]. No randomized clin-
ical trial enabled the evaluation of the reduction in
mortality through BPC screening in the specific popula-
tion of subjects professionally exposed to lung carcino-
gens. Based on the literature published on the risk of
bronchopulmonary cancer associated with tobacco con-
sumption, the relative risk of bronchopulmonary cancer
for smokers with a consumption of over 30 pack years
(PY) is estimated to be equal to or in excess of 30; for
smokers with a consumption between 20 and 30 PY, it is
estimated at 20, and for those with a consumption be-
tween 10 and 20 PY, it is estimated at 10 [29]. In former
smokers who have stopped smoking within the past
15 years, the relative risk of BPC is estimated to be five
[29]. No occupational carcinogen considered alone ob-
tains the same level of risk in non-smokers (except for
arsenic and BCME).
In order to propose screening in accordance with the
NLST criteria and to account for occupational risk fac-
tors, we needed to consider the types of occupational ex-
posures among smokers and former smokers that had a
risk level at least equivalent to the NLST results. Hence,
in Table 2, the working group proposed an estimation of
the relative risk (RR) of each occupational lung carcino-
gen and tobacco, based on the available data in the lit-
erature. For all carcinogens included in the rationale, we
assumed that the cumulative effect of two risk factors on
the risk of bronchopulmonary cancer was multiplied.
For example, in a subject with a risk level of 30, adopt-
ing a multiplicative model for former smokers who have
not smoked for over 15 years and have been exposed to
soot, the risk of bronchopulmonary cancer was esti-
mated to be 5 × 2 = 10. We considered the fact that for
subjects with a high risk of bronchopulmonary cancer in
the NLST study, the RR was approximately 30. In
Table 2, the following is provided:
– in normal topography – subjects for whom the
estimated relative risk of bronchopulmonary cancer
is lower than that of NLST subjects;
– in bold italic – subjects for whom the estimated
relative risk is close to that of the NLST subjects,
i.e., between 30 and 60; and
– in bold underlined – subjects for whom the
estimated relative risk is higher than that of the
NLST subjects, i.e., equal to or above 60.
In the review of the literature focusing on occupational
risk factors for BPC, the reported studies included sub-
jects with highly varied periods of occupational expos-
ure, ranging from less than 1 year to the total duration
of their professional career. Hence, and from a prag-
matic point of view, the mean risks calculated in Table 2
apply to subjects with an exposure duration of 10 years.
Asbestos exposure is defined based on the report
provided by the jury of the 1999 French consensus
conference on the follow-up of asbestos-exposed
workers [30].
– High cumulative exposure: Confirmed, high level
and continued exposure of a duration equal to or in
excess of 1 year. For example, professional activities
in manufacturing or in the transformation of
materials including asbestos and their equivalents
when working on materials or equipment likely to
discharge asbestos fibers (e.g., fireproofing, naval
construction); Confirmed, high level and
discontinued exposure of a duration equal to or in
excess of 10 years (e.g., mechanics/machine
operators on heavy goods vehicle brake systems,
cutting of asbestos cement).
– Intermediate cumulative exposure: All other
documented situations with significant occupational
exposure. The majority of these situations involve
working with materials or equipment likely to
discharge asbestos fibers.
From a practical point of view, high-level exposure
corresponds roughly to a fiber concentration above ten
fibers/ml (8 h Time-Weighted Average (TWA)) and an
intermediate level to a fiber concentration above 0.1 f/
ml (8 h TWA).
Discussion
Simulation studies have been conducted since the publi-
cation of the NLST results in an attempt to better define
the groups of subjects who may benefit from chest CT
scan screening. These studies demonstrated that the
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higher the risk of bronchopulmonary cancer among sub-
jects included in a screening procedure, the more the
benefit-risk balance leaned towards benefit [31–35].
Among limitations of low-dose CT scan, we found false-
positives and overdiagnosis [36] but these limitations
could be reduced using appropriate reading and follow-
up protocol of lung nodules [37]. Another limitation of
screening by low-dose chest CT scan is the radiation ex-
posure due to the repetition of scan [36].In such condi-
tions, and given the lack of data on BPC screening in
occupationally exposed workers, the working group sug-
gests a strictly controlled experiment on BPC screening
in high-risk subjects, i.e., subjects with an occupational
exposure to lung carcinogens that indicates a high risk
of BPC.
The high-risk population as defined by the working
group is presented in Table 3
All other risk situations are to be considered on an in-
dividual basis by the responsible health care center.
Hence, the working group recommends the following:
Table 2 Estimation of BPC risk associated with occupational risk factors and tobacco consumption (Expert consensus)
Relative risk according







Agents, situations or processes <20 PY 20 – 29 PY ≥30 PY
Tobacco 1 5 10 20 30
Asbestos – intermediate cumulative level < 10 years 1.5 1.5 7.5 15 30 45
Asbestos – intermediate cumulative level ≥ 10 years 2 2 10 20 40 60
Asbestos – high cumulative level < 5 years 2.5 2.5 12.5 25 50 75
Asbestos – high cumulative level≥ 5 years 3 3 15 30 60 90
Asbestosis 3 3 15 30 60 90
Pleural plaques 2 2 10 20 40 60
Crystalline silica 1.5 1.5 7.5 15 30 45
Silicosis 2 2 10 20 40 60
Diesel exhaust fumes – intermediate level 1.5 1.5 7.5 15 30 45
Diesel exhaust fumes – high level 2 2 10 20 40 60
Aluminium production 2 2 10 20 40 60
Coal gasification 2 2 10 20 40 60
Coal tar pitch 2 2 10 20 40 60
Coke production 2 2 10 20 40 60
Soot 2 2 10 20 40 60
X-rays and gamma rays 2 2 10 20 40 60
Radon 2 2 10 20 40 60
Iron ore mines 2 2 10 20 40 60
Plutonium 10 10 50 100 200 300
Iron and steel foundry 1.5 1.5 7.5 15 30 45
Painting profession 2 2 10 20 40 60
Rubber production 2 2 10 20 40 60
Arsenic and its compounds 5 5 25 50 100 150
Nickel compounds 2 2 10 20 40 60
Chromium(VI) compounds 2 2 10 20 40 60
Beryllium 2 2 10 20 40 60
Cadmium and its compounds 2 2 10 20 40 60
Bis(chloromethyl) ether; Chloromethyl methyl ether 10 10 50 100 200 300
Metal cobalt associated with tungsten carbide 2 2 10 20 40 60
These RR estimations were retained by the working group based on data from the literature and on the hypothesis of the multiplicative joint effect of a
carcinogenic agent and tobacco
normal: risk level < 30; italic bold: 30 < risk level > 60; bold underlined: risk level ≥ 60
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– the implementation of a screening experiment for
bronchopulmonary cancer in subjects occupationally
exposed or having been occupationally exposed to
lung carcinogens confirmed as high-risk factors for
BPC using low-dose chest CT scan (Expert consen-
sus). This experiment, which will be conducted in
reference healthcare centers, should enable the
evaluation of the feasibility of such screening. More-
over, little studies have evaluated the cost-
effectiveness ratio of the BPC screnning. In NLST
this ratio was assessed at 52 000USD per year gained
[38]. Thus, experiment will be evaluated this cost-
effectiveness ratio.
– the assessment of individual bronchopulmonary
cancer risk to determine the most suitable medico-
professional surveillance for each worker. This as-
sessment must be based on professional and clinical
history and it should take into account all risk fac-
tors, including confirmed occupational lung carcino-
gens (IARC group 1) associated or not with tobacco
consumption.
– to encourage or to lead smokers, regardless of
eligibility for screening, to benefit from guidance on
how to stop smoking (Expert consensus)
Other than the screening experiment, the experts do
not recommend screening by low-dose chest CT scan
among workers currently or formerly occupationally ex-
posed to lung carcinogens (Expert consensus) (indeed,
given the lack of specific studies on this population and
of appropriately organized structures, the conditions
were considered insufficient to translate the results of
the North American NLST study to this population (Ex-
pert consensus)).
Following the conclusions of the working group, a re-
cent review of the literature on the effectiveness, accept-
ability and safety of lung cancer screening with LDCT in
subjects highly exposed to tobacco determined, in regard
to the lack of strong scientific evidence, that LDCT
screening should not be recommended in subjects with
high exposures to tobacco [39].
Conclusions
The working group’s proposal on the need to imple-
ment a screening experiment for bronchopulmonary
cancer, in subjects occupationally exposed or having
been occupationally exposed to lung carcinogens
confirmed as high-risk factors for BPC with low-
dose chest CT scan, is in line with previously inter-
nationally published recommendations and expert
opinions [12–21].
Endnotes
1List of Classifications by cancer sites with sufficient
or limited evidence in humans, Volumes 1 to 112,
IARC
Table 3 Definition of high-risk subjects for BPC (aged from 55 to 74 years) (Expert consensus)
Occupational pollutant Cumulative level of exposure or disease Cumulative exposure duration Active or former tobacco consumption
dating back less than 15 years
Asbestos Intermediateb ≥10 years ≥30 PY
High <5 years ≥30 PY
High ≥5 years ≥20 PY
Asbestosis ≥20 PY
Pleural plaques ≥30 PY
Other carcinogenic agentsa ≥10 years ≥30 PY
Co-exposure
2 carcinogenic agents ≥10 years ≥20 PY
≥ 3 carcinogenic agents ≥10 years ≥10 PY
aaluminium production, coal gasification, coal tar pitch, coke production, X-rays and gamma rays, radon, iron ore mines, plutonium, steel foundries, the painting
profession, rubber production, chromium(VI) compounds, beryllium, cadmium and its compounds, bis(chloromethyl) ether, chloromethyl methyl ether, metal
cobalt with tungsten carbide
Special cases: Crystalline silica (silicosis is necessary to integrate the high-risk group for BPC, independently of the duration of exposure); diesel engine exhaust
fumes (a high level of exposure defined by employment in underground mines, tunnel construction or underground mine maintenance is necessary to integrate
the high-risk group for BPC)
bIn the sense of the jury of the 1999 french consensus conference on the follow-up of asbestos-exposed workers
High exposure: Confirmed, high and continued exposure of a duration equal to or in excess of one year; examples: professional activities in the manufacture or
transformation of materials including asbestos and their equivalents during intervention on materials or equipment likely to discharge asbestos fibres (e.g.:
fireproofing, naval construction); Confirmed, high and discontinued exposure of a duration equal to or in excess of 10 years (e.g.: mechanics/machine operators
on heavy goods vehicle brake systems, cutting of asbestos cement)
Intermediate exposure: All other documented occupational significant exposure situations. The majority of these situations involve intevention on materials or
equipment likely to discharge asbestos fibres
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